Abstract
Atopic dermatitis (AD) is a common inflammatory skin condition. The newly FDA approved biologic dupilumab has demonstrated significant improvement in the signs and symptoms of AD, including pruritus as well as those of anxiety and depression1. The most frequently reported adverse effects of dupilumab include injection site reactions, nasopharyngitis, upper respiratory infections, and conjunctivitis 1-5. We report a case of dupilumab-induced psoriasiform dermatitis. To our knowledge, there have been no reports to date of a dupilumab-induced psoriasiform dermatitis. There has been one report of an erythrodermic presentation of psoriasis in a patient treated with dupilumab8. As novel immunotherapy treatments are developed and employed in the treatment of common conditions such as AD, it is important to better understand and be aware of the potential side effects and immune-based sequelae that may arise in addition to available treatment options for these adverse reaction.
Highlights
A 40-year-old Indian male with a long-standing history of severe atopic dermatitis (AD), asthma, and allergic rhinitis was started on dupilumab after failing multiple treatment modalities
Figure 2: pink to erythematous pathces to thin plaques on the forehead extending into the scalp with fine white flaky scale
AD is a complex immunologic disorder characterized by the overexpression of Th2 cytokines, with IL-4 and IL-13 among the primary inflammatory mediators
Summary
Karlee; Veenstra, Jesse; Siegel, Dana; and Kerr, Holly, "Dupilumab Induced Psoriasiform Dermatitis" (2019). Following is fourth injection he developed a new asymptomatic pink scaly rash on his forehead and trunk in addition to red, itchy, watery eyes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
